Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Up 1,934.4% in April

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 65,100 shares, a growth of 1,934.4% from the March 31st total of 3,200 shares. Based on an average daily trading volume, of 92,600 shares, the short-interest ratio is presently 0.7 days.

Wall Street Analyst Weigh In

Separately, Brookline Capital Management cut shares of Antibe Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 4th.

Antibe Therapeutics Stock Performance

Shares of OTCMKTS ATBPF remained flat at $0.22 during midday trading on Thursday. Antibe Therapeutics has a 12 month low of $0.11 and a 12 month high of $0.89. The company’s 50-day simple moving average is $0.38 and its 200-day simple moving average is $0.53.

Antibe Therapeutics (OTCMKTS:ATBPF) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. On average, analysts anticipate that Antibe Therapeutics will post -0.31 EPS for the current year.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).